Ad
ASND Short Information Ascendis Pharma A/S
home / stock / asnd / asnd short
| Twenty Trading Day Totals | |
|---|---|
| Total Shorted Volume | 3,073,651 |
| Total Actual Volume | 8,464,713 |
| Short Trends | |
|---|---|
| Cover Days | 0 |
| Short Days | 19 |
| No Change Days | 1 |
| Averages | |
|---|---|
| Average Short Volume | 153,683 |
| Average Short Percentage | 70.74% |
Is there a ASND Short Squeeze or Breakout about to happen?
See the ASND Short Analysis for free Sign up or Login
Powered by Squeeze Report
ASND Twenty Trading Day's Volume to Short Volume Chart
ASND Twenty Trading Day Price Chart
ASND Short Data Results Days
| Stock Date | Open Price | Close Price | High | Low | Total Volume | Short Volume | Short Percentage |
|---|---|---|---|---|---|---|---|
| 2022-08-09 | 98.36 | 89.28 | 98.79 | 92.79 | 624,810 | 339,477 | 83.7611 |
| 2022-08-08 | 95.28 | 89.28 | 100.04 | 94.96 | 1,414,129 | 503,081 | 79.1639 |
| 2022-08-05 | 90.07 | 89.28 | 95.29 | 88.9 | 1,149,457 | 451,186 | 80.3051 |
| 2022-08-04 | 89.49 | 89.28 | 92.77 | 89.05 | 496,289 | 183,545 | 78.0903 |
| 2022-08-03 | 86.96 | 89.28 | 89.98 | 86.825 | 197,894 | 54,696 | 69.5710 |
| 2022-08-02 | 83.92 | 89.28 | 87.71 | 83.92 | 320,159 | 115,135 | 85.2460 |
| 2022-08-01 | 85.08 | 89.28 | 87.11 | 83.61 | 164,796 | 46,768 | 75.2284 |
| 2022-07-29 | 86.29 | 89.28 | 87.88 | 84.8375 | 239,427 | 56,430 | 57.5276 |
| 2022-07-28 | 89.28 | 89.28 | 89.98 | 85.25 | 207,575 | 33,054 | 40.4108 |
| 2022-07-26 | 86.3 | 86.3 | 87.64 | 85.05 | 161,807 | 165,609 | 93.1680 |
| 2022-07-25 | 89.07 | 87.02 | 89.07 | 85.1 | 303,472 | 70,103 | 63.0083 |
| 2022-07-19 | 87.18 | 87.94 | 88.02 | 85.5 | 157,682 | 34,001 | 61.1100 |
| 2022-07-18 | 85.86 | 85.5 | 88.57 | 85.17 | 684,301 | 300,349 | 81.0204 |
| 2022-07-15 | 86.34 | 85.33 | 86.34 | 82.7 | 863,324 | 369,674 | 79.7605 |
| 2022-07-14 | 87.48 | 85.57 | 88.32 | 85.21 | 162,803 | 44,297 | 57.0749 |
| 2022-07-13 | 89.33 | 88.57 | 92.42 | 87.76 | 319,532 | 68,854 | 65.4493 |
| 2022-07-12 | 91.28 | 90.06 | 92.65 | 87.705 | 265,961 | 91,853 | 80.9399 |
| 2022-07-11 | 93.22 | 90.77 | 93.22 | 90.52 | 241,055 | 51,002 | 73.6310 |
| 2022-07-06 | 95.49 | 89.5 | 95.8 | 88.76 | 347,356 | 68,443 | 56.4832 |
| 2022-07-05 | 91.46 | 95.39 | 95.72 | 91.15 | 142,884 | 26,094 | 53.7943 |
News, Short Squeeze, Breakout and More Instantly...
Ad
Ad
-
— U.S. regulatory submission for TransCon PTH, designed to be the first parathyroid hormone replacement therapy, on track for Q3 2022; EU submission planned for Q4 2022 — SKYTROFA revenue continued to double quarter-to-quarter, reaching Ȋ...
-
COPENHAGEN, Denmark, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, August 10, 2022, at 4:30 p.m. Eastern Time (ET) to review its second quarter 2022 financial results and provi...
-
– Late-breaker oral presentation of TransCon PTH Phase 3 PaTHway Trial data in adult hypoparathyroidism on Tuesday, June 14 – Oral presentation of TransCon PTH Phase 2 PaTH Forward Trial Open-Label Extension Data in adult hypoparathyroidism on ...
Ad
Important Investor News Alert (OTCMKTS: GTCH)
-
San Diego, CA - August 10, 2022 (Investorideas.com Newswire) GBT Technologies Inc. ( OTC PINK: GTCH ) ("GBT" or the "Company"), filed a second continuation patent application for its 3D, Multi-Planar IC design and manufacturing technology application, focusing on memory microchips a...